- Home
- GITS vs SILO Comparison
GITS vs SILO Comparison
Compare GITS & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- SILO
- Stock Information
- Founded
- GITS 2018
- SILO 2010
- Country
- GITS South Korea
- SILO United States
- Employees
- GITS N/A
- SILO N/A
- Industry
- GITS
- SILO Apparel
- Sector
- GITS
- SILO Consumer Discretionary
- Exchange
- GITS Nasdaq
- SILO Nasdaq
- Market Cap
- GITS 7.0M
- SILO 5.9M
- IPO Year
- GITS N/A
- SILO N/A
- Fundamental
- Price
- GITS $2.51
- SILO $0.73
- Analyst Decision
- GITS
- SILO
- Analyst Count
- GITS 0
- SILO 0
- Target Price
- GITS N/A
- SILO N/A
- AVG Volume (30 Days)
- GITS 22.9K
- SILO 889.2K
- Earning Date
- GITS 08-15-2025
- SILO 11-11-2025
- Dividend Yield
- GITS N/A
- SILO N/A
- EPS Growth
- GITS N/A
- SILO N/A
- EPS
- GITS N/A
- SILO N/A
- Revenue
- GITS $29.00
- SILO $72,102.00
- Revenue This Year
- GITS N/A
- SILO $1.86
- Revenue Next Year
- GITS N/A
- SILO N/A
- P/E Ratio
- GITS N/A
- SILO N/A
- Revenue Growth
- GITS N/A
- SILO N/A
- 52 Week Low
- GITS $0.87
- SILO $0.41
- 52 Week High
- GITS $9.78
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- GITS 53.01
- SILO 56.93
- Support Level
- GITS N/A
- SILO $0.58
- Resistance Level
- GITS $2.74
- SILO $0.83
- Average True Range (ATR)
- GITS 0.17
- SILO 0.05
- MACD
- GITS -0.05
- SILO 0.01
- Stochastic Oscillator
- GITS 91.61
- SILO 58.27
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.